Abstract
Fifteen Alzheimer (AD) and fifteen normative (NM) age-matched autopsy brains were analyzed in superior temporal cortex, hippocampal and brainstem samples. Vascular endothelial growth factor (VEGF) positive capillaries were quantitatively analyzed in all three sites in the 30 cases. Amyloid β42 senile plaques and VEGF positive capillaries were counted and statistically analyzed using Mann-Whitney, Kruskal–Wallis and the non-parametric Spearman’s test. There is a significantly different expression of capillary VEGF between normative and Alzheimer brains. Within Alzheimer’s superior temporal, hippocampus and brainstem sites there was reduced VEGF expression, with the P value being less than 0.05 in all three sites (superior temporal less than 0.035, hippocampus less than 0.001, brainstem less than 0.006). As VEGF is an important endothelial growth factor involved in vascular remodeling, angiogenesis, and endothelial/blood brain barrier maintenance, its reduced expression in Alzheimer’s disease is evidence for altered capillary function in this disease, which may be contributory to its pathogenesis by altering beta amyloid handling and efflux.
Keywords: Alzheimer's disease, blood-brain barrier, senile plaques, VEGF.
Current Neurovascular Research
Title:Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease
Volume: 11 Issue: 3
Author(s): John Provias and Brian Jeynes
Affiliation:
Keywords: Alzheimer's disease, blood-brain barrier, senile plaques, VEGF.
Abstract: Fifteen Alzheimer (AD) and fifteen normative (NM) age-matched autopsy brains were analyzed in superior temporal cortex, hippocampal and brainstem samples. Vascular endothelial growth factor (VEGF) positive capillaries were quantitatively analyzed in all three sites in the 30 cases. Amyloid β42 senile plaques and VEGF positive capillaries were counted and statistically analyzed using Mann-Whitney, Kruskal–Wallis and the non-parametric Spearman’s test. There is a significantly different expression of capillary VEGF between normative and Alzheimer brains. Within Alzheimer’s superior temporal, hippocampus and brainstem sites there was reduced VEGF expression, with the P value being less than 0.05 in all three sites (superior temporal less than 0.035, hippocampus less than 0.001, brainstem less than 0.006). As VEGF is an important endothelial growth factor involved in vascular remodeling, angiogenesis, and endothelial/blood brain barrier maintenance, its reduced expression in Alzheimer’s disease is evidence for altered capillary function in this disease, which may be contributory to its pathogenesis by altering beta amyloid handling and efflux.
Export Options
About this article
Cite this article as:
Provias John and Jeynes Brian, Reduction in Vascular Endothelial Growth Factor Expression in the Superior Temporal, Hippocampal, and Brainstem Regions in Alzheimer`s Disease, Current Neurovascular Research 2014; 11 (3) . https://dx.doi.org/10.2174/1567202611666140520122316
DOI https://dx.doi.org/10.2174/1567202611666140520122316 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Agents: VTA or VDA
Current Bioactive Compounds Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research Epigenetics of Aging
Current Genomics Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Current Diabetes Reviews The Impact of Dementia Development Concurrent with Parkinson's Disease: A New Perspective
CNS & Neurological Disorders - Drug Targets Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Uric Acid and Cu/Zn Superoxide Dismutase: Potential Strategies and Biomarkers in Functional Recovery of Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Chronic Hypoxia Potentiates Age-Related Oxidative Imbalance in Brain Vessels and Synaptosomes
Current Neurovascular Research Zederone Improves the Fecal Microbial Profile in Dementia Induced Rat Model: A First Report
CNS & Neurological Disorders - Drug Targets Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design Environment, Physical Activity, and Neurogenesis: Implications for Prevention and Treatment of Alzhemiers Disease
Current Alzheimer Research Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Converging Pathways in the Occurrence of Endoplasmic Reticulum (ER) Stress in Huntingtons Disease
Current Molecular Medicine tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Microbial Agents, Immune Function and Atheromatosis: The Chlamydophila pneumoniae Role
Current Immunology Reviews (Discontinued) The Impact of Pharmaceutical Care Practice on the Practitioner and the Patient in the Ambulatory Practice Setting: Twenty-five Years of Experience
Current Pharmaceutical Design Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways
Current Neuropharmacology Neural Correlates in Patients with Major Affective Disorders: An fMRI Study
CNS & Neurological Disorders - Drug Targets Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research